Search live federal opportunities

PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79726R0009 for an unrestricted procurement for Fluticasone/Salmeterol Inhaler, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Ma

Rabeprazole Contract Award is attached.

Award Document for Dextroamphetamine-Amphetamine ER - SPE2D2-26-D-0005

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implement

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implement

Fexofenadine Tablets SPE2D2-25-D-0005 Option 1

SPE2D2-25-D-0006 P00002 to exercise Option Year 1 effective February 05, 2026 through February 04, 2027. SPE2D2-25-D-0006 P00001 is modified in accordance with DoD Class Deviation 2025-O0003. SPE2D2-25-D-0006 Atenolol Tablets Award

Amendment 0002

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implement

National Contract Award to AvKARE, LLC. (SPE2D2-26-D-0002) for Telmisartan Tablets originally solicited under SPE2D2-24-R-0015.

Amendment 5 is being issued to re-open the solicitation and proceed with source selection activities. Reinstate Jennifer Gartzke as the point of contact. The attached SF30 contains additional information.

Los Alamos National Laboratory scientists have developed high-affinity human antibodies that can quickly detect and potentially treat deadly, antibiotic-resistant plague infections, helping protect against both natural outbreaks and bioterror threats. The Cha

SPE2D2-22-D-0140 P00008 to exercise Option Year 4 effective December 08, 2025 through December 07, 2026. SPE2D2-22-D-0140 P00007 is modified in accordance with DoD Class Deviation 2025-O0003. SPE2D2-22-D-0140 P00006 to exercise Option Year 3 effective Decemb

P0004 is being issued to exercise the first year option.

SPE2D2-26-D-0004 Morphine IR & ER Tablets Award

This innovation from scientists at Los Alamos National Laboratory is a significant improvement on a gold standard protein purification method that gently captures and releases antibodies using mild pH changes, making antibody purification safer, more efficient

Amendment 0004 has been issued to extend the solicitation to July 08, 2025.

Award for Fluconazole Tablets solicited under SPE2D2-25-R-0009.

Amendment 0001 has been issued to extend the solicitation closing date to November 3, 2025. All other terms and conditions of the solicitation remain unchanged.

Modification to announce exercise of the second year option.

MOD P00009 issued to exercise Option Year Three (3).

NATIONAL CONTRACT SPE2D2-22-D-0144 VALSARTAN

Posting of the award to AvKare.

Award for Solifenacin solicited under SPE2D2-25-D-0017.

Modification P00008 SPE2D223D0002 is issued to invoke option year 3 for Bupropion HCL ER National Contract. Modification P00007 SPE2D223D0002 is issued in accordance with DoD Class Deviation 2025-O0003 and Class Deviation 2025-O0004 into subject solicitation.